Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jan 6;25(1):7.
doi: 10.1186/s12905-024-03513-1.

Effectiveness and tolerability of lactic acid vaginal gel compared to oral metronidazole in the treatment of acute symptomatic bacterial vaginosis: a multicenter, randomized-controlled, head-to-head pilot study

Fiona Tidbury  1 , Grégory Brülhart  2 , Gabriela Müller  2 , Elena Pavicic  1 , Susanna Weidlinger  1 , Gerrit Eichner  3 , Michael von Wolff  1 , Petra Stute  4
Affiliations
Randomized Controlled Trial

Effectiveness and tolerability of lactic acid vaginal gel compared to oral metronidazole in the treatment of acute symptomatic bacterial vaginosis: a multicenter, randomized-controlled, head-to-head pilot study

Fiona Tidbury et al. BMC Womens Health. .

Abstract

Background: Bacterial vaginosis (BV) is a prevalent vaginal condition among reproductive-age women, characterized by off-white, thin vaginal discharge with a fishy odor. It increases susceptibility to sexually transmitted diseases (STDs) and pelvic inflammatory disease (PID). BV involves a shift in vaginal microbiota, with reduced lactobacilli and increased anaerobic bacteria. Standard treatment with oral metronidazole has been shown to have a limited long-term efficacy, possibly due to biofilm persistence. Alternative treatments, such as lactic acid vaginal gel, aim to restore vaginal pH and lactobacilli. This pilot study compares the efficacy and tolerability of lactic acid gel to standard oral metronidazole for acute BV treatment in non-pregnant women.

Methods: A total of 32 women with acute BV were recruited and assigned to either the treatment group (n = 16) where they applied a lactic acid vaginal gel for 12 days, or the control group (n = 16) which received 500 mg oral metronidazole twice daily for seven days. A number of objective and subjective parameters including the Amsel score, the Nugent score and a subjective symptom score were recorded at day 0, three weeks, three months, and six months after the study start.

Results: In the short-term, lactic acid vaginal gel showed inferior clinical (Amsel criteria) and microbiological (Nugent score) cure rates compared to metronidazole. However, it performed equally well regarding subjective symptom improvement and BV recurrence prevention after up to six months.

Conclusion: Lactic acid vaginal gel was generally very well tolerated and showed mixed but promising results as a stand-alone treatment for acute BV.

Trial registration number: NCT02042287 (22.01.2014).

Keywords: Bacterial vaginosis; Lactic acid; Metronidazole; Randomized controlled trials; Vaginal microbiome.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: Ethical approval was granted by the cantonal ethics committee Bern (No. 2016_01992). Informed consent was obtained from all individual participants included in the study. Competing interests: FT, GB, GM, GE, EP, MvW and SW declare no relevant financial or non-financial interests. PS has received honoraria from Tentan AG for presentations at conferences.

Figures

Fig. 1
Fig. 1
Change in symptom score. Non-parametric repeated measures ANOVA-type test: p = 0.817 for the interaction between time and treatment
See this image and copyright information in PMC

References

    1. Sobel JD. Bacterial vaginosis. Annu Rev Med. 2000;51:349–56. - PubMed
    1. Wiesenfeld HC, Hillier SL, Krohn MA, Landers Dv, Sweet RL. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis. 2003;36(5):663–8. - PubMed
    1. Schwebke JR. Gynecologic consequences of bacterial vaginosis. Obstet Gynecol Clin North Am. 2003;30(4):685–94. - PubMed
    1. Tidbury FD, Langhart A, Weidlinger S, Stute P. Non-antibiotic treatment of bacterial vaginosis-a systematic review. Arch Gynecol Obstet. 2021;303(1):37–45. - PubMed
    1. Hill GB. The microbiology of bacterial vaginosis. Am J Obstet Gynecol. 1993;169(2 Pt 2):450–4. - PubMed

Publication types

Associated data

LinkOut - more resources